Pancreatic Cancer Treatment Market Size, Share & COVID-19 Impact Analysis, By Type (Exocrine and Endocrine), By Treatment Type (Chemotherapy, Radiation Therapy, and Others), By End-user (Hospitals, Clinics, and Others), and Regional Forecast, 2022-2029

The pancreatic cancer treatment market size was valued at USD 2.15 billion in 2021 and is projected to grow from USD 2.48 billion in 2022 to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029. North America dominated the global market with a share of 46.97% in 2022.

Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used in the treatment.

• For instance, according to an article published by GLOBOCAN, approximately 56,654 new cases of pancreatic cancer were reported in 2020 in the U.S. Moreover, 47,683 deaths occurred owing to cancer in the United Sates.


• According to an article published by Macmillan Cancer Support U.K., around 10,500 new cases of pancreatic cancer were diagnosed in the U.K. in 2019.

Moreover, the prevalence is significantly higher in the geriatric population compared to other types of cancers. Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth. The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers. The increase in the number of patients suffering from the condition has increased the demand for the drugs used in treatment. These are some factors driving the growth during the forecast period

Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment. Additionally, the companies operating in the market have received approval from several regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others, thereby propelling the growth of the market. Moreover, new testing technologies are being adopted by hospitals and diagnostic centers to diagnose cancer. The increase in the diagnosis rates is driving the demand for drugs, thereby providing opportunities for the players.

• For instance, in December 2019, the U.S. Food and Drug Administration (FDA) approved the use of olaparib to treat patients suffering from metastatic pancreatic cancer.

COVID-19 IMPACT 

Significant Decline in Cancer Screening and Patient Visits during COVID-19 Pandemic Slowed Down Market Growth

The number of patient visits for cancer screening declined during the pandemic owing to the presence of limited personnel performing these procedures. Moreover, the governments of several countries introduced new regulations, thereby leading to a decline in surgical and diagnostic procedures to reduce the spread of COVID-19. Moreover, several patients canceled their chemotherapy and radiation therapy appointments due to the risk of infection. The cancellation of the appointment led to a decline in the demand for medicines. This led to a decline in the sale of the drugs used for pancreatic type of cancer treatment.

• For instance, Sutent, a drug used for pancreatic cancer treatment, generated a revenue of USD 819.0 million in 2020 and witnessed a decline of 13.0% compared to USD 936.0 million in 2019.


• According to the survey done by NCBI, several healthcare centers performed fewer pancreatic surgeries due to the COVID-19 pandemic, which reduced the weekly pancreatic resection rate from 3 to 1.

However, revoking lockdown restrictions, introducing products by key players in the market, and re-establishing the supply chain network increased the demand for drugs for the treatment of cancer in 2021. Moreover, the number of cancer patient visits began returning to normal owing to higher vaccination coverage among the general population, the introduction of COVID-19 protocols in public places, the dismissal of restrictions for travel, and others. This led to an increase in demand for pancreatic cancer treatment drugs.

• For instance, in 2021, Pfizer Inc.’s drug product sales, including the drugs used for pancreatic cancer treatment, recovered by 2% compared to 2020.

LATEST TRENDS

Presence of Potential Pipeline Products to Drive the Market Growth

Shifting the focus of key players in extensive R&D activities to develop new drugs and an increase in funding for cancer research led to the development of new drugs for treatment. Additionally, several pharmaceutical companies are involved in clinical trials to develop new drugs and explore the potential of the molecule to treat the disease.

• For instance, in March 2019, Clovis Oncology published the data from the Rubraca (rucaparib) Phase 2 study in advanced pancreatic cancer, demonstrating the safety and efficacy of (rucaparib) in platinum-sensitive patients.


• Moreover, in August 2021, Aravive Inc. dosed the first patient in the Phase Ib portion of its Phase Ib/II trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced pancreatic adenocarcinoma. The Phase Ib portion of the clinical trial will analyze the tolerability, safety, pharmacodynamics, and pharmacokinetics of AVB-500 in combination with gemcitabine and nab-paclitaxel.

Thus, with the increased funding for R&D activities, companies are focused on developing new drugs, thereby contributing to the overall rise in demand for drugs for pancreatic type of cancer treatment.

DRIVING FACTORS

Increasing Prevalence of Pancreatic Cancer to Augment Market Growth

The prevalence has increased significantly in the past few years, leading to an increase in the adoption of several treatment options.

• For instance, according to GlOBOCAN, around 14,461 new cases of pancreatic cancer were detected in France in 2020. The rate of incidences of new cases of this cancer was 7.9 per 100,000 men and 4.6 per 100,000 women in France.


• According to an article published by NCBI, around 21,859 new cases of pancreatic cancer were reported in Germany in 2021. The increase in cigarette smoking and the rise in tobacco consumption are some of the factors leading to the increase in cases of this cancer.

The increasing incidence among the population, coupled with government initiatives, is expected to propel the adoption of pancreatic cancer treatment drugs.

• For instance, according to a study published by the Korean Cancer Association in 2019, in Korea, cancer screening is provided to all people over 50 at no or minimal cost by the National Cancer Screening Program. The increasing aging population and government initiatives are expected to propel the adoption of screening tests, thereby presenting a large patient pool requiring treatment.

Thus, increasing aging population and rising government initiatives to create awareness for the diagnosis of the condition are some factors propelling the market growth.

RESTRAINING FACTORS

High Cost and Side Effects Associated with Treatment Likely to Hinder Market Growth

The constant focus of market players on introducing new drugs has resulted in an increase in the cost of pancreatic cancer treatment. This has led to a shift in patient preference toward alternative treatment options, such as herbal therapy, which costs less than regular treatment.

• For instance, according to the American Society of Clinical Oncology, a six-month course of chemotherapy (Gemcitabine) costs around USD 23,500. With the combination of the drug Erlotinib, the treatment costs reach around USD 40,000.

This along with side effects associated with chemotherapy drugs such as pain, fever, dizziness, vomiting, and frequent bloody bowel movements are limiting their adoption. Additionally, shortness of breath, diarrhea, urinary and bladder problems, and changes in taste are some of the side effects associated with radiation therapy, which are likely to hamper the market growth.

Thus, the high cost associated with treatment and adverse reactions associated with chemotherapy and radiation therapy is expected to limit the market growth in the forecast period.

SEGMENTATION

By Type Analysis

Increasing Adoption of Advanced Technologies for Diagnosis to Drive the Market Growth

Based on type, the market is classified into exocrine and endocrine.

The exocrine segment captured the largest market share in 2021. Exocrine cancer is more prevalent among patients. The majority of the pancreas is composed of exocrine cells forming the exocrine glands and ducts. The cancer cell development in the pancreas's ducts affects the pancreas's exocrine part. Cancer cell development occurs less in the endocrine part of the pancreas. Thus, owing to these factors, the diagnosis and the prevalence of exocrine pancreatic cancer are significantly high.

• For instance, according to an article published by the European Society for Medical Oncology, approximately 95% of diagnosed cancers are exocrine.

The increase in adoption of advanced technologies and increasing awareness among consumers regarding pancreatic endocrine tumors among the population are driving the growth of the segment.

Moreover, the increase in adoption of new technologies has led to an increase in the diagnosis of pancreatic endocrine cancer. Moreover, pancreatic endocrine tumors are more prevalent in the geriatric population. Thus, the increase in geriatric population, coupled with the increase in number of patients suffering from pancreatic neuroendocrine tumors, is expected to drive the growth of the segment.

• For instance, according to the American Cancer Society, approximately 4,300 people in the U.S. were diagnosed with pancreatic neuroendocrine tumors in 2022.

By Treatment Type Analysis

Increasing Adoption of Chemotherapy Drugs is expected to drive the Market Growth

Based on treatment type, the market has been segmented into chemotherapy, radiation therapy, and others.

The chemotherapy segment constituted the largest market share in 2021. Chemotherapy is used as the first line of treatment. Many patients suffering from this cancer receive chemotherapy, which provides long-term cancer protection. It eliminates the rapidly dividing abnormal cells and involves the application of chemicals and lasers to eradicate all diseased cells.  

• For instance, according to a report published by Lancet Oncology, around 9.8 million cancer patients worldwide received chemotherapy in 2018, and approximately 15 million cancer patients across the globe are anticipated to receive chemotherapy by 2040

The radiation therapy segment is expected to grow during the forecast period. An increase in the adoption of advanced technologies across hospitals and clinics to treat cancer patients has led to the adoption of advanced radiation therapy equipment.

• For instance, in August 2022, India’s Apollo Proton Cancer Centre (APCC) inked an agreement with Ion Beam Applications (IBA), Belgium, to provide proton-based radiation therapy training for clinicians.


• For instance, in August 2021, Manipal Hospitals, India’s second-largest multi-specialty hospital, launched an advanced Radixact System that comes with Synchrony Automatic, Real-time Motion Synchronization Technology for the precise treatment of cancer patients.

Thus, owing to these factors, the demand for radiation therapy is anticipated to rise in the coming years.

By End-user Analysis

Shifting Consumer Preference toward Hospitals to Propel the Segment Growth

Based on end-user, the market is classified into hospitals, clinics, and others.

Hospitals segment captured the largest market share in 2021. The majority of the patients receive primary care at hospitals. The segment's growth is primarily attributed to the increase in number of patients taking chemotherapy, radiation therapy, and other treatments at hospitals. The adoption of new technologies by hospitals for the diagnosis and treatment of this condition is expected to drive the growth of the segment.

The clinics segment accounted for a significant market share in the global market. The increase in the number of cancer patients visiting clinics for treatment is propelling the growth of the segment.

• For instance, according to the Centre for Disease Control and Prevention (CDC), around 650,000 cancer patients across the U.S. received treatment at outpatient clinics in the U.S. in 2020.

Thus, an increase in the number of clinics providing radiation therapy and chemotherapy and an increase in the privatization for the establishment of clinics contribute to expanding the clinic’s segment.

REGIONAL INSIGHTS

The market in North America was valued at USD 1.01 billion in 2021. The presence of advanced healthcare facilities and the adoption of new technologies used in diagnosis constitute the growth of the market in the region. Additionally, the increase in prevalence of the condition across the U.S. and the presence of established players in the region are propelling the growth of the pancreatic market in the region.

• According to an article published by the National Institutes of Health (NIH), around 89,248 people in the U.S. in 2021 were living with pancreatic cancer. The rate of the incidences of new cases of this cancer was 13.3 per 100,000 men and women per year.

Europe held the second-largest pancreatic cancer treatment market share. The prevalence of the condition is significantly high across Germany, France, Italy, and Spain. The growth in the region is attributed to the increase in R&D investment by major players, favorable government regulations, and the launch of awareness programs by the government are some of the factors propelling the market growth in the region.

• For instance, in 2021, Servier Hellas Pharmaceutique Ltd organized a program at the French Embassy to increase awareness of pancreatic cancer across France.

Asia Pacific is anticipated to expand at the highest CAGR during the forecast period. The rising prevalence, improvement in healthcare infrastructure, and increase in the number of pharmaceutical companies developing products for pancreatic cancer treatment are some of the factors propelling the growth of the region.

• According to the Janssen Asia Pacific, Asia Pacific hosts 50% of the world’s new cancer cases each year, and deaths caused by cancer in Asia are expected to increase by 36.0% by 2030. Asia Pacific is expected to be one of the hotspots for cancer. The increase in new cancer cases across the region increases the demand for drugs, driving the treatment of this cancer.

The market in the Middle East & Africa and Latin America is likely to grow at a slower pace. The increase in the geriatric population and the increase in prevalence of the condition are accelerating the market growth in the region.

• For instance, in 2020, according to GLOBOCAN, 13,307 new cases of pancreatic cancer were reported in Brazil.

KEY INDUSTRY PLAYERS

Strong Focus on Collaborations by Key Players to Strengthen their Market Position

In terms of the competitive landscape, majority of the global market share is held by AstraZeneca, Pfizer Inc., and Novartis AG. These companies are the leading players offering innovative drugs. The major factors responsible for the leading position in the market are the regulatory approval for new products, product launches, mergers, and acquisition of the competitive players. Additionally, PharmaCyte Biotech, Inc. and Clovis Oncology are also some of the key players operating in the market. Moreover, an increase in investment in the development of advanced products has enabled AstraZeneca to hold a leading position in the market.

• For instance, in January 2022, AstraZeneca collaborated with Scorpion Therapeutics to discover, develop, and commercialize precision medicines against previously hard-to-target cancer proteins.

Moreover, Novartis AG is also focused on establishing collaborations and agreements with other players to bolster its presence across other countries.

• For instance, in December 2021, the company strengthened its immunotherapy pipeline by entering into a collaboration and licensing agreement with BeiGene for TIGIT inhibitor ociperlimab. The company gained the right to develop and commercialize ociperlimab in the U.S., Canada, and other countries through this agreement.

LIST OF KEY COMPANIES PROFILED:

• AstraZeneca (U.K.)


• Novartis AG (Switzerland)


• Pfizer Inc. (U.S.)


• Genentech (F. Hoffmann-La Roche Ltd) (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Ipsen Pharma (France)


• Oncolytics Biotech, Inc. (Canada)


• TME Pharma (Germany)


• Erytech Pharma (France)


• Clovis Oncology, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• January 2022 –Novartis AG received an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It combines with other chemotherapy drugs to treat pancreatic cancer and other tumors.


• September 2021 – F. Hoffmann-La Roche Ltd partnered with NovoCure to develop Tumor Treating Fields (TTFields) in combination with anti-PD-L1 therapy, atezolizumab, for patients diagnosed with metastatic pancreatic ductal adenocarcinoma (mPDAC).


• December 2020 – Bristol-Myers Squibb Company announced positive results from the phase III clinical trial, CheckMate – 548. The trial evaluated the efficacy of Opdivo in patients with newly diagnosed glioblastoma multiforme.


• June 2020 – Ipsen pharma received fast-track designation by the U.S. Food and Drugs Administration (FDA) for the use of the liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin known as NALIRIFOX for the treatment of patients suffering from locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC).


• December 2019 – AstraZeneca and Merck & Co. Inc., in collaboration, received the U.S. FDA approval for Lynparza (olaparib) for its use in the U.S. for the maintenance treatment of patients suffering from pancreatic cancer.

REPORT COVERAGE

The research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, type, treatment type, and end-user. Besides this, the market analysis highlights key industry developments and insights into market trends.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2018-2029
Base Year	2021
Estimated Year	2022
Forecast Period	2022-2029
Historical Period	2018-2020
Unit	Value (USD billion)
Segmentation	By Type, Treatment Type, End-user, and Region
By Type	Exocrine Endocrine
By Treatment Type	Chemotherapy Radiation Therapy Others
By End-user	Hospitals Clinics Others
By Region	North America (By Type, By Treatment Type, By End-user, and By Country) U.S. (By Type) Canada (By Type) Europe (By Type, By Treatment Type, By End-user, and By Country/Sub-region) Germany (By Type) U.K. (By Type) France (By Type) Italy (By Type) Spain (By Type) Rest of Europe (By Type) Asia Pacific (By Type, By Treatment Type, By End-user, and By Country/Sub-region) India (By Type) China (By Type) Japan (By Type) Australia (By Type) Rest of Asia Pacific (By Type) Latin America (By Type, By Treatment Type, By End-user, and By Country/Sub-region) Brazil (By Type) Mexico (By Type) Rest of Latin America (By Type) Middle East & Africa (By Type, By Treatment Type, By End-user, and By Country/Sub-region) GCC (By Type) South Africa (By Type) Rest of Middle East & Africa (By Type)